Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Baseline characteristics and laboratory parameters according to Klotho tertiles. | Full Cohort | Klotho Tertile 1 | Klotho Tertile 2 | Klotho Tertile 3 | P value | | 339 [260 to 427]N = 239 | (<286 pg/ml) N = 75 | (286 to 392 pg/ml)N = 75 | (>392 pg/ml)N = 77 |: 25(OH)vitamin D (ng/ml) | 28 [21]: [35] | 28 [20]: [35] | 27 [21]: [34] | 29 [20]: [36] | 0.52

Source: Results table. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Patients were eligible if they had given written informed consent, initiation of hemodialysis was more than three months previously and there was no evidence of acute life-threatening illness, cardiac event, cardiac amyloidosis or cardiac procedure within the previous two months.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Prognostic Value and Link to Atrial Fibrillation of Soluble Klotho and FGF23 in Hemodialysis Patients

Study design awaiting verification · PLoS ONE · 2014

Original publication title

Prognostic Value and Link to Atrial Fibrillation of Soluble Klotho and FGF23 in Hemodialysis Patients

Albina Nowak; Björn Friedrich; Ferruh Artunc; Andreas L. Serra; Tobias Breidthardt; Raphael Twerenbold; Myriam Peter; Christian Mueller

© 2014 Nowak et al

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

Deranged calcium-phosphate metabolism contributes to the burden of morbidity and mortality in dialysis patients. This study aimed to assess the association of the phosphaturic hormone fibroblast growth factor 23 (FGF23) and soluble Klotho with all-cause mortality. We measured soluble Klotho and FGF23 levels at enrolment and two weeks later in 239 prevalent hemodialysis patients. The primary hypothesis was that low Klotho and high FGF23 are associated with increased mortality. The association between Klotho and atrial fibrillation (AF) at baseline was explored as secondary outcome.

AF was defined as presence of paroxysmal, persistent or permanent AF. During a median follow-up of 924 days, 59 (25%) patients died from any cause. Lower Klotho levels were not associated with mortality in a multivariable adjusted analysis when examined either on a continuous scale (HR 1.25 per SD increase, 95% CI 0.84 to 1.86) or in tertiles, with tertile 1 as the reference category (HR for tertile two 0.65, 95% CI 0.26 to 1.64; HR for tertile three 2.18, 95% CI 0.91 to 2.23). Higher Klotho levels were associated with the absence of AF in a muItivariable logistic regression analysis (OR 0.66 per SD increase, 95% CI 0.41 to 1.00).

Higher FGF23 levels were associated with mortality risk in a multivariable adjusted analysis when examined either on a continuous scale (HR 1.45 per SD increase, 95% CI 1.05 to 1.99) or in tertiles, with the tertile 1 as the reference category (HR for tertile two 1.63, 95% CI 0.64 to 4.14; HR for tertile three 3.91, 95% CI 1.28 to 12.20). FGF23 but not Klotho levels are associated with mortality in hemodialysis patients. Klotho may be protective against AF.

Authors’ abstract

Deranged calcium-phosphate metabolism contributes to the burden of morbidity and mortality in dialysis patients. This study aimed to assess the association of the phosphaturic hormone fibroblast growth factor 23 (FGF23) and soluble Klotho with all-cause mortality. We measured soluble Klotho and FGF23 levels at enrolment and two weeks later in 239 prevalent hemodialysis patients. The primary hypothesis was that low Klotho and high FGF23 are associated with increased mortality. The association between Klotho and atrial fibrillation (AF) at baseline was explored as secondary outcome.

AF was defined as presence of paroxysmal, persistent or permanent AF. During a median follow-up of 924 days, 59 (25%) patients died from any cause. Lower Klotho levels were not associated with mortality in a multivariable adjusted analysis when examined either on a continuous scale (HR 1.25 per SD increase, 95% CI 0.84 to 1.86) or in tertiles, with tertile 1 as the reference category (HR for tertile two 0.65, 95% CI 0.26 to 1.64; HR for tertile three 2.18, 95% CI 0.91 to 2.23). Higher Klotho levels were associated with the absence of AF in a muItivariable logistic regression analysis (OR 0.66 per SD increase, 95% CI 0.41 to 1.00).

Higher FGF23 levels were associated with mortality risk in a multivariable adjusted analysis when examined either on a continuous scale (HR 1.45 per SD increase, 95% CI 1.05 to 1.99) or in tertiles, with the tertile 1 as the reference category (HR for tertile two 1.63, 95% CI 0.64 to 4.14; HR for tertile three 3.91, 95% CI 1.28 to 12.20). FGF23 but not Klotho levels are associated with mortality in hemodialysis patients. Klotho may be protective against AF.

Publication and source details

Original title: Prognostic Value and Link to Atrial Fibrillation of Soluble Klotho and FGF23 in Hemodialysis Patients

Albina Nowak; Björn Friedrich; Ferruh Artunc; Andreas L. Serra; Tobias Breidthardt; Raphael Twerenbold; Myriam Peter; Christian Mueller

PLoS ONE · 2014

* E-mail: albina.nowak@usz.ch

Competing Interests: The authors declare that TECOmedical AG, Switzerland measured the soluble Klotho and FGF23 levels in their hemodialysis cohort for this study. The authors of this manuscript have no commercial or professional association with TECOmedical AG. They have nothing to declare concerning employment, consultancy, patents, products in development, marketed products, etc. This does not alter the authors’ adherence to PLOS ONE policies on sharing data and materials.

Conceived and designed the experiments: AN BF FA CM. Performed the experiments: BF FA. Analyzed the data: AN AS. Contributed reagents/materials/analysis tools: AN BF FA TB RT MP. Wrote the paper: AN.

© 2014 Nowak et al2014Nowak et alhttps://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.The authors thank TECOmedical AG, Switzerland for measurements of soluble Klotho and FGF23 levels. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. In addition to the above, there was no other funding for this study. The authors’ organisations had no other external or internal funding.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-12T20:46:08.839403+00:00

DOI: 10.1371/journal.pone.0100688 · PMC4084634